TY - JOUR
T1 - Secukinumab in the Treatment of Psoriasis
T2 - A Narrative Review on Early Treatment and Real-World Evidence
AU - Malagoli, Piergiorgio
AU - Dapavo, Paolo
AU - Amerio, Paolo
AU - Atzori, Laura
AU - Balato, Anna
AU - Bardazzi, Federico
AU - Bianchi, Luca
AU - Cattaneo, Angelo
AU - Chiricozzi, Andrea
AU - Congedo, Maurizio
AU - Fargnoli, Maria Concetta
AU - Giofrè, Claudia
AU - Gisondi, Paolo
AU - Guarneri, Claudio
AU - Lembo, Serena
AU - Loconsole, Francesco
AU - Mazzocchetti, Giampiero
AU - Mercuri, Santo Raffaele
AU - Morrone, Pietro
AU - Offidani, Anna Maria
AU - Palazzo, Giovanni
AU - Parodi, Aurora
AU - Pellacani, Giovanni
AU - Piaserico, Stefano
AU - Potenza, Concetta
AU - Prignano, Francesca
AU - Romanelli, Marco
AU - Savoia, Paola
AU - Stingeni, Luca
AU - Travaglini, Massimo
AU - Trovato, Emanuele
AU - Venturini, Marina
AU - Zichichi, Leonardo
AU - Costanzo, Antonio
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/10
Y1 - 2024/10
N2 - Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.
AB - Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.
KW - Early treatment
KW - Psoriasis
KW - Secukinumab
KW - Treatment
UR - https://www.scopus.com/pages/publications/85204681224
U2 - 10.1007/s13555-024-01255-4
DO - 10.1007/s13555-024-01255-4
M3 - Review article
SN - 2193-8210
VL - 14
SP - 2739
EP - 2757
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 10
ER -